首页> 外文期刊>Drug Design, Development and Therapy >Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis
【24h】

Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis

机译:沙利司他治疗腹部脓毒症急性肺损伤/急性呼吸窘迫综合征的临床评价

获取原文
       

摘要

Background: The efficacy of sivelestat in the treatment of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) has not been established. In part, this is due to the wide variety of factors involved in the etiology of ALI/ARDS. In this study, we examined the efficacy of sivelestat in patients with ALI/ARDS associated with abdominal sepsis.Methods: The subjects were 49 patients with ALI/ARDS after surgery for abdominal sepsis. The efficacy of sivelestat was retrospectively assessed in two treatment groups, ie, a sivelestat group (n = 34) and a non-sivelestat group (n = 15).Results: The sivelestat group showed significant improvements in oxygenation, thrombocytopenia, and multiple organ dysfunction score. The number of ventilator days (6.6 ± 6.1 versus 11.1 ± 8.4 days; P = 0.034) and length of stay in the intensive care unit (8.5 ± 6.2 versus 13.3 ± 9.5 days; P = 0.036) were significantly lower in the sivelestat group. The hospital mortality rate decreased by half in the sivelestat group, but was not significantly different between the two groups.Conclusion: Administration of sivelestat to patients with ALI/ARDS following surgery for abdominal sepsis resulted in early improvements of oxygenation and multiple organ dysfunction score, early ventilator weaning, and early discharge from the intensive care unit.
机译:背景:尚无ilelestat治疗急性肺损伤/急性呼吸窘迫综合征(ALI / ARDS)的疗效。部分原因是由于ALI / ARDS的病因涉及多种因素。在这项研究中,我们检查了西乐司他对伴有腹部脓毒症的ALI / ARDS患者的疗效。方法:受试者为49名患有腹部脓毒症的ALI / ARDS患者。回顾性分析了两个治疗组中西乐司他的疗效,即西乐司他组(n = 34)和非西乐司他组(n = 15)。结果:西乐司他组显示出氧合,血小板减少和多器官功能明显改善功能障碍评分。 Silelestat组的呼吸机天数(6.6±6.1对11.1±8.4天; P = 0.034)和重症监护病房的住院时间(8.5±6.2对13.3±9.5天; P = 0.036)显着降低。西乐司他组的医院死亡率降低了一半,但两组之间无显着差异。结论:腹部脓毒症手术后对ALI / ARDS患者使用西乐司他可早期改善氧合和多器官功能障碍评分,早期呼吸机断奶,以及从重症监护室早期排出。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号